



REASON STUDY BROCHURE

One small gene. One big REASON to learn about this research study.

The REASON Study is evaluating the safety of an investigational drug designed to target the *LRRK2* gene, potentially slowing the progression of Parkinson's disease (PD).

If you are living with Parkinson's disease, the REASON clinical study may be of interest to you.

[LRRK2 AND PARKINSON'S]

What is *LRRK2*?

The leucine-rich repeat kinase 2 (*LRRK2*) gene is a gene responsible for the development of LRRK2 protein. Mutations in the *LRRK2* gene (which provides instructions for making the LRRK2 protein) are known to be associated with PD. Previous research studies have shown that one of the reasons for PD may be having too much LRRK2 protein in the brain.

The REASON study is evaluating an investigational drug designed to potentially reduce how much LRRK2 is produced, by blocking some of the genetic instructions the body uses to create this protein. Researchers believe this may lead to decreased LRRK2 protein development, and a possible improvement in PD symptoms.

[ELIGIBILITY OVERVIEW]

The REASON Study

The REASON Study is a phase 1 study, which means it is the first to test the study drug in humans. The study is evaluating the safety of an investigational drug for patients with PD. The goal of the clinical trial is to answer questions about the investigational therapy's safety and how it moves through the body.

Who Can Join?

You may be eligible to participate if you:

- Are 35 to 80 years of age
- Were diagnosed with PD within the last 7 years
- Are not currently receiving, or are on a stable dose of, oral Parkinson's medication

All eligible study participants will receive at no cost:

- Comprehensive study-related health evaluations and assessments
- Investigational drug or placebo
- All study-related visits and care

[STUDY OVERVIEW]

Study Overview

The study includes two parts: Part A and Part B. Each part will have screening, treatment and follow-up periods. Participants may be invited to take part in Part A, Part B, or both.

Part A:

- 18 weeks long
- Receive the investigational drug or placebo once
- 75% of participants will receive the investigational drug and 25% will receive placebo.

Study participants are assigned to receive either the study drug or placebo at random (by chance). A placebo is a substance that looks like the investigational drug but contains no actual active drug. Neither study participants nor the study team will be told which group they have been placed into. Investigational drug or placebo will be administered intrathecally – in an injection into the lower back near the spine.

Part B:

- 47 weeks long
- Receive the investigational drug or placebo four times
- 75-80% of participants will receive the investigational drug and 20-25% will receive placebo.

[CALL TO ACTION]**Where to Start**

If you have an interest in study participation, speak with a member of the study staff today – you will be given an opportunity to speak with the study doctor and their staff to ask any questions you may have.

Participation in a clinical research study is always voluntary. If you decide to participate, you may withdraw at any time and for any reason. If you decide not to participate, your decision will not affect the care you are receiving now or may receive in the future.

Talk to a study doctor today to see if the REASON Study is right for you.

For more information visit ClinicalTrials.gov.